BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Yao LT, Wang MZ, Wang MS, Yu XT, Guo JY, Sun T, Li XY, Xu YY. Neoadjuvant endocrine therapy: A potential strategy for ER-positive breast cancer. World J Clin Cases 2019; 7(15): 1937-1953 [PMID: 31423426 DOI: 10.12998/wjcc.v7.i15.1937]
URL: https://www.wjgnet.com/2307-8960/full/v7/i15/1937.htm
Number Citing Articles
1
Tingting Wei, Xia Li, Wanmin Qiang, Yan Zhang, Hailing Ren, Qiupeng Zhang, Xue Jin. Menopausal symptoms in breast cancer patients receiving adjuvant endocrine therapy and their relationships with health-promoting behaviors and social supportMenopause 2023; 30(3): 289 doi: 10.1097/GME.0000000000002130
2
Huayao Li, Chundi Gao, Qing Liang, Cun Liu, Lijuan Liu, Jing Zhuang, Jing Yang, Chao Zhou, Fubin Feng, Changgang Sun. Cryptotanshinone Is a Intervention for ER-Positive Breast Cancer: An Integrated Approach to the Study of Natural Product Intervention MechanismsFrontiers in Pharmacology 2021; 11 doi: 10.3389/fphar.2020.592109
3
Ryeo-Eun Go, Cho-Won Kim, Sung-Moo Lee, Hong Kyu Lee, Kyung-Chul Choi. Fenhexamid induces cancer growth and survival via estrogen receptor-dependent and PI3K-dependent pathways in breast cancer modelsFood and Chemical Toxicology 2021; 149: 112000 doi: 10.1016/j.fct.2021.112000
4
Yi Li, Kexin Wang, Yupeng Chen, Jieqi Cai, Xuemei Qin, Aiping Lu, Daogang Guan, Genggeng Qin, Weiguo Chen. A System Pharmacology Model for Decoding the Synergistic Mechanisms of Compound Kushen Injection in Treating Breast CancerFrontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.723147
5
Nandini Dey, Jennifer Aske, Pradip De. Targeted Neoadjuvant Therapies in HR+/HER2−Breast Cancers: Challenges for Improving pCRCancers 2021; 13(3): 458 doi: 10.3390/cancers13030458